Drugs Made In America Acquisition Corp. (DMAAR) EPS (Basic) (2025 - 2026)
Drugs Made In America Acquisition's (DMAAR) quarterly EPS (Basic) came in at $0.04 in Q2 2026, down 21.99% on a YoY basis from $0.05 in Q2 2025, and up 645.96% quarter-over-quarter from $0.0 in Q4 2025.
Powered by 
Analysis
Drugs Made In America Acquisition Corp. (DMAAR) EPS (Basic) (2025 - 2026) Analysis & Trends
Drugs Made In America Acquisition (DMAAR) has reported EPS (Basic) for 2 consecutive years, with $0.04 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EPS (Basic) fell 21.99% year-over-year to $0.04; the trailing twelve-month figure through Jun 2026 stood at $0.14 (changed N/A YoY), and the FY2025 full-year result was $0.13, up 486.26% from the prior year.
- EPS (Basic) improved to $0.04 in Q2 2026 per DMAAR's latest filing, from $0.0 in the prior quarter.
- Across five years, EPS (Basic) topped out at $0.05 in Q2 2025 and bottomed at $0.0 in Q4 2025.
Peer Set
Peer Comparison
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.04 |
| Dec 31, 2025 | 0.00 |
| Sep 30, 2025 | 0.04 |
| Jun 30, 2025 | 0.05 |
| Mar 31, 2025 | 0.03 |